Financial Planning Experts

Breaking Financial News and Information
Menu
  • Entrepreneurs
  • World Finance
  • Breaking News
  • Markets
  • Real Estate
  • Privacy Policy
  • Contact Us

Abbott attributes Q3 sales decline to baby formula shortage, less COVID-19 testing

Bill Muskegy October 19, 2022

Abbott Laboratories
ABT,
+1.41%
said Wednesday that it had earnings of $1.4 billion, or $1.15 per share, in the third quarter of 2022, compared with $2.1 billion, or $1.40, in the same quarter a year ago. Adjusted earnings per share were $1.15, against a FactSet consensus of 94 cents. The company reported that sales fell 4.7% to $10.4 billion in the third quarter, driven by declining sales in its nutrition business, which has been dealing with shortages of baby formula since the start of the year, and falling sales of COVID-19 tests. The FactSet consensus for total sales in the quarter was $9.6 billion. Total nutrition sales are down 14.9% to $1.8 billion, and sales in its diagnostics business tumbled 6.2% to $3.6 billion. Abbott said it raised adjusted EPS for the year to $5.17 to $5.23. The company’s stock is down 25.4% this year, while the broader S&P 500
SPX,
+1.14%
has declined 21.9%.

Prev Article
Next Article

Related Articles

Keep on Buying Tesla Stock, Says Analyst Ahead of ‘Master Plan Part 3’
That Tesla (TSLA) is a law unto itself is already …

Keep on Buying Tesla Stock, Says Analyst Ahead of ‘Master Plan Part 3’

7 things you may have missed amid this week’s banking crisis
Today’s newsletter is by Brian Sozzi, executive editor at Yahoo …

7 things you may have missed amid this week’s banking crisis

About The Author

Bill Muskegy



Recent Posts

  • Credit Card Affin Bank
  • Credit Card Junior
  • Hh Credit Card
  • Dwr Credit Card
  • Credit Card Square Vs Stripe

Financial Planning Experts

Breaking Financial News and Information
Copyright © 2023 Financial Planning Experts
Theme by Financial Planning

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Refresh